Transdermal formulation of nicardipine hydrochloride
US4637930A · kind A · utility
24Cited by
3References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 31, 1985 |
| Grant date | Jan 20, 1987 |
| Priority date | — |
| Expiry date | Jan 31, 2005 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K47/26
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A formulation is provided for the transdermal administration of nicardipine hydrochloride. The formulation is comprised of nicardipine hydrochloride dissolved or suspended in a mixed liquid composed of an urea and at least one compound selected from the group consisting of propylene glycol, a monohydric alcohol having 2 to 4 carbon atoms, lactic acid, thioglycol, a middle chain fatty acid glyceride and a sorbitan middle chain fatty acid ester compounded with a transdermal formulation base.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.